Spine device company K2M closed on their initial public offering earlier this year and the IPO's underwriters exercised their over-allotment option, according to a company news release.
The underwriters exercised their option to purchase 1 million shares of common stock from the selling stakeholders at a price of $15 per share before underwriting discounts. The over-allotment option closed on June 10 and K2M will not receive any proceeds from the sale of these shares.
Pipar Jaffray & Co., Barclays Capital and Wells Fargo Securities acted as joint book-running managers for the offering. William Blair & Company and Cowen and Company acted as co-managers.
More Articles on Medical Devices:
5 Key Cost & Quality Findings on Spinal Fusion vs. coflex
Orthocell Launches IPO: 3 Key Facts
Behind the K2M IPO: CEO Eric Major Talks Strategy, Innovation & Future Financial Growth